INIS
patients
100%
cancer
85%
pancreas
53%
metastases
27%
adenocarcinomas
22%
chemotherapy
22%
tumors
21%
surgery
20%
populations
17%
netherlands
12%
diseases
11%
combined therapy
11%
data
10%
therapy
10%
comparative evaluations
10%
esophagus
7%
solids
7%
risks
7%
doses
7%
toxicity
7%
reviews
5%
safety
5%
radiotherapy
5%
hepatomas
5%
Keyphrases
Pancreatic Cancer
23%
Overall Survival
21%
Netherlands
13%
Pancreatic Ductal Adenocarcinoma
13%
Chemotherapy
12%
Borderline Resectable Pancreatic Cancer
8%
Median Overall Survival
8%
National Cohort Study
7%
Resection
7%
Gemcitabine
7%
Cancer Patients
7%
Resectable Pancreatic Cancer
7%
Treatment Survival
6%
Periampullary Cancer
6%
Dutch
6%
Advanced Solid Tumors
6%
Population-based Study
6%
Pancreaticoduodenectomy
6%
Adjuvant Chemotherapy
5%
Cancer Registry
5%
Immediate Surgery
5%
Neoadjuvant Chemoradiotherapy (nCRT)
5%
FOLFIRINOX
5%
Confidence Interval
5%
Intestinal Microbiota
5%
Esophageal Cancer
5%
Hepatocellular Carcinoma
5%
Medicine and Dentistry
Pancreas Cancer
35%
Overall Survival
25%
Pancreas Adenocarcinoma
15%
Surgery
14%
Chemoradiotherapy
13%
Malignant Neoplasm
13%
Chemotherapy
12%
Neoplasm
8%
Systemic Therapy
8%
Cohort Analysis
8%
Gemcitabine
8%
Randomized Controlled Trial
6%
Pancreaticoduodenectomy
6%
Adjuvant Chemotherapy
5%
Radiation Therapy
5%
Cancer Registry
5%
Cancer Therapy
5%
Colorectal Carcinoma
5%